Quest Diagnostics Research and Development Expenses 2010-2024 | DGX

Quest Diagnostics annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Quest Diagnostics research and development expenses for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
  • Quest Diagnostics research and development expenses for the twelve months ending September 30, 2024 were $0M, a NAN% increase year-over-year.
  • Quest Diagnostics annual research and development expenses for 2023 were $0B, a NAN% decline from 2022.
  • Quest Diagnostics annual research and development expenses for 2022 were $0B, a NAN% decline from 2021.
  • Quest Diagnostics annual research and development expenses for 2021 were $0B, a NAN% decline from 2020.
Quest Diagnostics Annual Research and Development Expenses
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Quest Diagnostics Quarterly Research and Development Expenses
(Millions of US $)
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $17.877B $9.252B
Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $20.039B 12.12
DaVita (DVA) United States $12.667B 16.38
Encompass Health (EHC) United States $10.405B 24.53
Chemed (CHE) United States $8.459B 26.00
Elanco Animal Health (ELAN) United States $7.054B 16.79
RadNet (RDNT) United States $6.388B 141.61
Option Care Health (OPCH) United States $3.890B 18.43
Amedisys (AMED) United States $3.035B 21.60
LifeStance Health (LFST) United States $2.828B 0.00
Addus HomeCare (ADUS) United States $2.320B 27.22
Astrana Health (ASTH) United States $2.297B 36.01
U.S Physical Therapy (USPH) United States $1.428B 37.54
Pennant (PNTG) United States $1.162B 46.99
Aveanna Healthcare Holdings (AVAH) United States $1.149B 0.00
Atai Life Sciences (ATAI) Germany $0.265B 0.00
Daxor (DXR) United States $0.042B 0.00
Psychemedics (PMD) United States $0.014B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.014B 0.00
ATI Physical Therapy (ATIP) United States $0.011B 0.00
Ontrak (OTRK) United States $0.008B 0.00
IMAC Holdings (BACK) United States $0.001B 0.00